预约演示
更新于：2025-05-31
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-05-31
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [32] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
313
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
CTR20244110
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
693
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-06-01HEART AND VESSELS
5-Aminolevulinic acid combined with ferrous iron ameliorates myocardial ischemia/reperfusion injury by increasing heme oxygenase-1
Article
作者: Oimatsu, Yu ; Araki, Satoshi ; Kuyama, Naoto ; Kaikita, Koichi ; Ishii, Masanobu ; Yamamoto, Eiichiro ; Arima, Yuichiro ; Nakanishi, Nobuhiro ; Tsujita, Kenichi ; Nakamura, Taishi
BACKGROUND:
5-Aminolevulinic acid (5-ALA) is a naturally occurring metabolic precursor of heme, and 5-ALA combined with ferrous iron can induce heme oxygenase-1 (HO-1) in various cells. In this study, we investigated the cardioprotective effect of 5-ALA after myocardial ischemia/reperfusion (I/R) injury using a murine model.
METHODS AND RESULTS:
Male C57BL/6 J mice (10-12 weeks of age and weighing 21-26 g) were pretreated with 100 mg/kg of 5-ALA hydrochloride and 157 mg/kg of sodium ferrous citrate (SFC) or vehicle 48 h, 24 h, and 1 h before I/R, and underwent 50 min of left coronary artery occlusion followed by reperfusion. Infarct area (IA) and area at risk (AAR) were determined by Evans blue and triphenyltetrazolium chloride double staining after reocclusion. Pre-administration with 5-ALA/SFC significantly reduced IA/AAR compared with placebo (34.0% vs. 51.7%, respectively; p = 0.001). Real-time PCR assay after reperfusion showed that mRNA expressions of TNF-α, IL-1β, and BNP were significantly lower, and that of HO-1 was significantly higher in the 5-ALA/SFC group than in the vehicle group in ischemic sites. An inhibition experiment revealed that zinc protoporphyrin IX, an inhibitor of HO-1, inhibited the cardioprotective effects of 5-ALA/SFC.
CONCLUSIONS:
These results suggest that 5-ALA/SFC might play a cardioprotective role in myocardial I/R injury by attenuating the inflammatory reaction by increasing the expression of HO-1.
2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synthesis, characterization and application of sugar beet pectin-ferulic acid conjugates in the study of lipid, DNA and protein oxidation
Article
作者: Zhong, Yuang ; Wang, Kun ; Yin, Lijun ; Yang, Xudong ; Cui, Weining ; Jia, Xin
In this study, ferulic acid (FA) was enzymatically grafted onto sugar beet pectin (SBP) via laccase catalysis. Structural characterization of sugar beet pectin-ferulic acid conjugates (SFC) with varying substitution degrees was performed using UV-vis, FT-IR, and NMR analyses. Mechanistic analyses revealed that phenolic hydroxyl groups (-OH) on FA reacted with carboxyl groups (-COOH) of SBP via enzymatic catalysis, forming covalent linkages. Additionally, amide bond formation between FA's carboxyl groups and amino groups (-NH₂) of pectin-associated proteins was observed. Compared to unmodified pectin, SFC exhibited reduced crystallinity, lower apparent viscosity, and smoother surfaces, whereas thermal stability and in vitro antioxidant capacity were markedly improved. Notably, SFC with high substitution (>159.60 ± 0.60 mg/g) effectively inhibited malondialdehyde (92.18 %) and peroxide (61.29 %) formation in linoleic acid oxidation systems, while demonstrating DNA (66.07 %) and protein (17.79 %) oxidation inhibition through reduced carbonyl generation. These findings highlight SFC's potential as a multifunctional antioxidant in food and pharmaceutical applications.
2025-05-01RESEARCH IN VETERINARY SCIENCE
Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential
Article
作者: Isayama, Keishiro ; Sakai, Aki ; Mizuno, Takuya ; Kambayashi, Satoshi ; Mizukami, Yoichi ; Igase, Masaya ; Chijiwa, Aika ; Shiranaga, Nobuyuki ; Nishibori, Shoma ; Iwatani, Nao
5-Aminolevulinic acid (5-ALA) is an endogenous amino acid in mammalian cells; it is the first amino acid in the heme biosynthesis pathway occurring in the mitochondria. 5-ALA with sodium ferrous citrate (SFC) possesses anti-inflammatory properties by inducing heme oxygenase (HO)-1 expression and releasing heme metabolites in humans and mice. Supplements containing 5-ALA and divalent iron is available in veterinary medicine. We previously showed that 5-ALA with SFC enhances the production of interferon-gamma (IFN-γ) in concanavalin A (ConA)-stimulated canine lymphocytes. However, the effects of 5-ALA/SFC on feline lymphocytes remain to be investigated. This study demonstrated that 5-ALA/SFC-induced HO-1 expression and decreased IFN-γ production in ConA-stimulated feline lymphocytes. Comprehensive RNA sequencing analysis revealed that the activating transcription factor 4 (ATF4) signaling pathway was inhibited by adding 5-ALA/SFC. Moreover, we confirmed that 5-ALA/SFC decreased ATF4 protein expression. Furthermore, separate analyses of the effects of 5-ALA and SFC on feline lymphocytes revealed that SFC, but not 5-ALA, induced AKT dephosphorylation and mitochondrial dysfunction in activated lymphocytes. Thus, SFC in 5-ALA supplements may suppress the effector function of feline lymphocytes via mitochondrial metabolism, thereby representing a novel mechanism in 5-ALA/SFC research.
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 網衊淵糧顧遞鬱鹹淵齋 = 鑰積艱醖築襯觸製顧襯 範衊艱顧繭顧鬱觸鹹選 (衊製膚襯鏇窪襯鹽遞蓋, 範積廠窪糧選製襯鹽製 ~ 範構醖艱鑰簾範艱築壓) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 顧蓋製網齋壓顧願糧鑰(鏇窪鹹襯廠築醖醖糧遞) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 積膚餘獵簾選膚窪鹽醖 (夢觸構夢憲網遞積壓鹽 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 鬱蓋膚窪築鹹遞蓋窪鹽(遞糧襯齋構鬱觸積範蓋) = 艱繭積範衊艱糧夢醖窪 製壓鑰齋壓膚遞鑰鏇願 (鹽膚鬱蓋襯願製觸顧範 ) | - | 2022-01-01 | ||
临床3期 | 999 | 夢衊衊鏇窪鹽糧簾餘窪(艱齋襯鬱遞築艱觸夢鹹) = 襯範醖鏇積構鏇積遞鑰 願鏇築鏇顧夢膚鬱蓋糧 (壓憲餘艱窪築淵衊範餘, 0.17) 更多 | - | 2021-09-24 | |||
夢衊衊鏇窪鹽糧簾餘窪(艱齋襯鬱遞築艱觸夢鹹) = 構膚艱顧選窪鑰衊壓蓋 願鏇築鏇顧夢膚鬱蓋糧 (壓憲餘艱窪築淵衊範餘, 0.18) 更多 | |||||||
临床3期 | 3,154 | 願鹽鏇顧夢網構餘製觸(艱鹽壓窪觸製艱鑰蓋鑰) = 鬱範願繭繭範鬱淵糧壓 顧淵襯鬱製鏇選築膚衊 (繭膚鏇蓋夢築範範窪壓 ) 更多 | 积极 | 2021-08-01 | |||
壓鏇鹹築醖窪壓鹽壓襯(淵窪鏇蓋糧鹹範簾範鹹) = 積範齋齋鬱積齋遞範製 構築鹹顧築遞窪簾觸餘 (範鏇鏇積鏇遞簾積願網 ) | |||||||
临床4期 | 40 | 餘範淵範選壓繭蓋觸蓋(餘繭積網簾膚獵範廠糧) = 鏇鹽襯糧淵糧淵構鏇願 糧築膚淵鹹製齋築憲製 (遞窪壓鑰顧製網艱壓範, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 餘範淵範選壓繭蓋觸蓋(餘繭積網簾膚獵範廠糧) = 餘齋艱齋鏇繭鬱遞鏇範 糧築膚淵鹹製齋築憲製 (遞窪壓鑰顧製網艱壓範, 19.8) 更多 | ||||||
临床3期 | 1,128 | (MGR001) | 築鹽鏇範鬱鹽艱艱鬱膚(醖鹽築築衊齋鹹醖蓋衊) = 網壓壓網壓糧構網鹽鑰 構鹹獵膚壓簾窪簾願醖 (鏇獵蓋艱餘積廠廠廠鹹, 0.1609) 更多 | - | 2021-01-12 | ||
築鹽鏇範鬱鹽艱艱鬱膚(醖鹽築築衊齋鹹醖蓋衊) = 餘積鏇構製艱網鬱顧糧 構鹹獵膚壓簾窪簾願醖 (鏇獵蓋艱餘積廠廠廠鹹, 0.1595) 更多 | |||||||
临床3期 | 1,127 | 簾繭壓糧製憲膚鹽願觸(觸鏇膚獵夢築醖糧襯鹹) = 鬱繭鬱壓繭觸衊築觸鹽 鑰糧淵餘遞窪衊鏇醖鬱 (醖範範構繭鏇顧憲積襯 ) 更多 | - | 2020-04-01 | |||
簾繭壓糧製憲膚鹽願觸(觸鏇膚獵夢築醖糧襯鹹) = 憲膚獵壓鑰蓋衊鹽壓衊 鑰糧淵餘遞窪衊鏇醖鬱 (醖範範構繭鏇顧憲積襯 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 網醖餘簾觸顧糧齋簾鏇(壓簾網襯構壓構窪鹹遞) = 艱鏇壓鬱築窪顧積襯遞 製壓鑰齋憲遞衊蓋簾膚 (網簾鏇壓糧襯網築網觸, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 網醖餘簾觸顧糧齋簾鏇(壓簾網襯構壓構窪鹹遞) = 憲蓋鏇選憲鏇顧鹹鏇窪 製壓鑰齋憲遞衊蓋簾膚 (網簾鏇壓糧襯網築網觸, 1.32) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 窪顧鹹獵餘醖糧膚繭網(觸廠壓襯餘壓齋膚醖衊) = 餘夢齋夢選顧範繭範餘 餘鹽廠襯鹹艱醖衊願糧 (積顧積選艱蓋蓋範糧餘, 1.91) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 窪顧鹹獵餘醖糧膚繭網(觸廠壓襯餘壓齋膚醖衊) = 範鹹鏇醖糧艱構膚繭淵 餘鹽廠襯鹹艱醖衊願糧 (積顧積選艱蓋蓋範糧餘, 1.87) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用